Steve is the co-lead of the Early Phase Clinical Trials work package. He is an academic clinical haematologist and combines the role of Clinical Senior Lecturer in the Institute of Cancer and Genetics at Cardiff University School of Medicine with clinical work as an Honorary Consultant Haematologist at the University Hospital of Wales where he serves as haematological cancer lead clinician.
Steve's clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia, the myeloproliferative neoplasms and myelodysplastic syndromes. His chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies; this includes pre-clinical laboratory studies of FLT3 inhibition, TAM-kinase inhibition and reactive oxygen species manipulation and clinical research including 'back-to-bench' laboratory projects running alongside clinical trials.
Steve is extensively involved in the development of clinical research at a national level through membership of the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. He is chief investigator of Monocle - a UK study of tefinostat in chronic myelomonocytic leukaemia, and co chief investigator of the AML18 and AML LI-1 trials. His other roles include Cardiff lead for the Leukaemia Lymphoma Research (now Bloodwise) Trials Acceleration Programme and lead of Cardiff School of Medicine medical undergraduate haematology teaching.